While there is an overall dearth of relevant information, including a lack of previous data on the dental disease experience or rates of disease on patients taking VEGF antagonists as well as minimal direct study of the conditions treated in these patients, there is no direct evidence available of a causative impact of the diseases treated in this population (macular degeneration, glaucoma, various primary and metastatic cancers) causing changes in dental status. Here, VEGFA is linked to metastatic malignant neoplasm.